Letter to the Editor
Hybrid histone deacetylase-kinase inhibitor potentiates venetoclax-induced cell death in chronic lymphocytic leukemia
Anali Del Milagro Bernabe Garniquea, Jorge Antonio Elias Godoy Carlosa, Natalia Sudan Parduccia, Mauricio Temotheo Tavaresb,c,d, Karoline de Barros Waitmanb, Keli Limaa,e, Leticia Veras Costa-Lotufoa, Roberto Parise-Filhob, João Agostinho Machado-Netoa,
Corresponding author
jamachadoneto@usp.br
Corresponding author. Department of Pharmacology, Institute of Biomedical Sciences of University of São Paulo, Av. Prof. Lineu Prestes, 1524, CEP 05508-900, São Paulo, SP, Brazil.
Corresponding author. Department of Pharmacology, Institute of Biomedical Sciences of University of São Paulo, Av. Prof. Lineu Prestes, 1524, CEP 05508-900, São Paulo, SP, Brazil.
a Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
b Department of Pharmacy, Faculty of Pharmaceutical Science, University of São Paulo, São Paulo, Brazil
c Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, United States
d Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, United States
e Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculty of Medicine, University of São Paulo, São Paulo, Brazil
